Broadcast Date: 
  • Time: 

Join us for an exclusive webinar as we delve into the world of acute myeloid leukemia (AML), an aggressive blood malignancy driven by leukemic stem cells (LSCs) that must be eradicated for disease cure. Genomic studies have demonstrated that AML develops from the sequential acquisition of multiple mutations that initially occur in pre-leukemic hematopoietic stem cells (pHSCs).

By understanding the biology of LSCs and pHSCs, Dr. Ravi Majeti and his team at Stanford University have paved the way for novel therapeutic strategies to combat AML. Learn about the pivotal role played by LSCs in driving AML and the critical insights gained from genomic studies.

Separately, Dr. Majeti will share their methods for reprogramming B-cell acute lymphoblastic leukemia (B-ALL) cells into antigen-presenting cells (APCs). Discover how these reprogrammed cells can stimulate leukemia-eradicating T cell immunity, presenting a promising avenue for treatment.

Don’t miss this opportunity to gain insights from a leading researcher in the field.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Ravi Majeti
Ravi Majeti, MD, PhD
Professor of Medicine
Stanford University

biotechne logo


Comments are closed.